Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis

Amit G. Singal1,2,3*, Anjana Pillai4, Jasmin Tiro2,3

1 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, 2 Department of Clinical Sciences, University of Texas Southwestern, Dallas, Texas, United States of America, 3 Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, 4 Department of Internal Medicine, Emory University, Atlanta, Georgia, United States of America

Abstract

Background: Surveillance for hepatocellular carcinoma (HCC) has level I evidence among patients with hepatitis B but only level II evidence in patients with cirrhosis. This lack of randomized data has spurred questions regarding the utility of HCC surveillance in this patient population; however, lack of randomized data does not equate to a lack of data supporting the efficacy of surveillance. The aim of our study was to determine the effect of HCC surveillance on early stage tumor detection, receipt of curative therapy, and overall survival in patients with cirrhosis.

Methods and Findings: We performed a systematic literature review using Medline from January 1990 through January 2014 and a search of national meeting abstracts from 2009–2012. Two investigators identified studies that reported rates of early stage tumor detection, curative treatment receipt, or survival, stratified by HCC surveillance status, among patients with cirrhosis. Both investigators independently extracted data on patient populations, study methods, and results using standardized forms. Pooled odds ratios, according to HCC surveillance status, were calculated for each outcome using the DerSimonian and Laird method for a random effects model. We identified 47 studies with 15,158 patients, of whom 6,284 (41.4%) had HCC detected by surveillance. HCC surveillance was associated with improved early stage detection (odds ratio [OR] 2.08, 95% CI 1.80–2.37) and curative treatment rates (OR 2.24, 95% CI 1.99–2.52). HCC surveillance was associated with significantly prolonged survival (OR 1.90, 95% CI 1.67–2.17), which remained significant in the subset of studies adjusting for lead-time bias. Limitations of current data included many studies having insufficient duration of follow-up to assess survival and the major not adjusting for liver function or lead-time bias.

Conclusions: HCC surveillance is associated with significant improvements in early tumor detection, receipt of curative therapy, and overall survival in patients with cirrhosis.

Please see later in the article for the Editors’ Summary.

Citation: Singal AG, Pillai A, Tiro J (2014) Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis. PLoS Med 11(4): e1001624. doi:10.1371/journal.pmed.1001624

Academic Editor: Paul Klenerman, University of Oxford, United Kingdom

Received September 16, 2013; Accepted February 21, 2014; Published April 1, 2014

Abbreviations: AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; OR, odds ratio; RFA, radiofrequency ablation; TNM, tumor node metastases.

* E-mail: amit.singal@utsouthwestern.edu

Introduction

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and one of the leading causes of death among patients with cirrhosis [1]. Its incidence in the United States and Europe is increasing due to the current epidemic of nonalcoholic steatohepatitis (NASH) and hepatitis C virus (HCV) cases [2]. Prognosis for patients with HCC depends on tumor stage, with curative therapies only available for patients detected at an early stage. Patients detected at an early stage can achieve 5-year survival rates of 70% with transplant or resection, whereas those with advanced HCC are only eligible for palliative treatments and have a median survival of less than one year [3,4].

The American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) guidelines recommend surveillance with ultrasound every 6 months in high-risk patients, i.e., those with chronic hepatitis B virus (HBV) infection and/or cirrhosis [5,6]. The goal of surveillance is to detect HCC at an early stage when it is amenable to curative therapy and to reduce all cause mortality. Although surveillance among HBV patients is supported by a large randomized controlled trial, there is no similar level I evidence supporting this practice among patients with cirrhosis [7]. Data
from patients with HBV cannot be directly extrapolated to patients with cirrhosis for several reasons, including a higher competing risk of non-HCC mortality and lower sensitivity of surveillance tools for HCC with a nodular liver [9]. The lack of randomized data has spurred questions regarding the utility of HCC surveillance in this patient population [9].

Given the lack of a randomized trial of HCC surveillance among patients with cirrhosis, a meta-analysis of cohort and case-control studies can serve to better characterize any potential benefits of HCC surveillance. The aim of our study was to determine the association of HCC surveillance with (i) detection of tumors at an early stage, (ii) receipt of curative therapies, and (iii) overall survival in patients with cirrhosis.

Methods

Data Sources and Searches

We conducted a computer-assisted search with the Ovid interface to Medline to identify relevant published articles. We search the Medline database from January 1, 1989 through January 1, 2014 with the following keyword combinations: (liver ca OR hepatocellular ca OR hcc OR hepatoma) AND (screen$ OR surveillance OR ultrasound). We chose to include studies after January 1989 to accurately reflect the current performance of ultrasonography and the current availability of curative therapies (including liver transplantation and radiofrequency ablation [RFA]). Manual searches of reference lists from applicable studies were performed to identify any studies that may have been missed by the computer-assisted search. Additional searches of AASLD, EASL, Digestive Diseases Week (DDW), American College of Gastroenterology (ACG), and American Society of Clinical Oncology (ASCO) meeting abstracts from 2010–2012 were performed. Finally, consultation with expert hepatologists was performed to identify additional references or unpublished data. This study was conducted in accordance with PRISMA guidelines [10].

Study Selection

Two investigators (AGS and AP) reviewed citations identified by the search strategy to generate a list of potentially relevant articles. The abstract for each potentially relevant study was then reviewed by each of the two investigators. If the applicability of a study could not be determined by title or abstract alone, the full text was reviewed. Articles were independently checked for possible inclusion and disagreements were resolved through consensus with a third reviewer (JT).

Studies were included for analysis if they (i) utilized ultrasound, with or without concomitant alpha fetoprotein (AFP), for HCC surveillance; (ii) performed surveillance in a cohort of patients with cirrhosis; and (iii) reported the number of HCC detected at an early stage, number of HCC patients who received curative therapies, and/or overall survival in both patients undergoing surveillance and those not undergoing surveillance. If a study included both patients with cirrhosis and chronic hepatitis, only data regarding patients with cirrhosis were extracted if possible. We included articles published in English or Spanish. We excluded studies that (i) evaluated one-time screening instead of surveillance or (ii) only reported outcome measures for patients undergoing surveillance but not for those without surveillance. Additional exclusion criteria included non-human data, lack of original data and incomplete reports. If duplicate publications used the same cohort of patients, data from the most recent article were included.

Data Extraction and Quality Assessment

Two reviewers (AGS and AP) independently extracted required information from eligible studies using standardized forms. A third investigator (JT) was available to resolve discrepancies between the two sets of extracted data. The data extraction form included the following study design items: characteristics and size of study cohort, inclusion and exclusion criteria, surveillance tests, surveillance interval, and definition of early stage disease. In addition, we recorded the following primary data for patients who received and did not receive surveillance: number of patients with HCC, proportion of HCC discovered at an early stage, proportion of patients who received curative treatments, and overall survival. Two investigators (AGS and AP) assessed study quality by a modified checklist based upon the Ottawa-Newcastle scale (ONS), with discrepancies resolved by consensus. This instrument rates observational studies on a nine-point scale based on appropriateness of study sample, comparability of study groups, and adequacy of assessing exposure and outcomes [11].

Data Synthesis and Statistical Analysis

For each individual study, an odds ratio for each outcome of interest was calculated according to receipt of surveillance (i.e., surveillance group versus non-surveillance group). Our first outcome of interest was the proportion of patients diagnosed with early stage HCC. Early stage HCC was defined by Milan criteria, i.e., one tumor less than 5 cm in maximum diameter or two to three lesions, each with a maximum diameter less than 3 cm [12]. Insufficient data on performance status and liver function in most studies precluded use of the Barcelona Clinic Liver Cancer (BCLC) staging system. The second outcome of interest was the proportion of patients with HCC who underwent curative therapy. Curative treatments included any of the following: liver transplantation, surgical resection, RFA, or percutaneous ethanol injection (PEI). Although transarterial chemoembolization (TACE) has been demonstrated to improve survival, it is regarded as palliative and was not included in our treatment outcome. Finally, our third outcome of interest was overall survival.

For each outcome of interest, we calculated a pooled odds ratio estimate with corresponding 95% confidence intervals, using the DerSimonian and Laird method for a random effects model. Heterogeneity was evaluated graphically by examination of forest plots and then statistically by the chi-squared test of heterogeneity and the inconsistency index (I²). A chi-squared p-value < 0.05 or I² values >50% are consistent with possible substantial heterogeneity [13,14]. Meta-influence analysis, in which one study is removed at a time, was performed to determine if there was possible undue influence of a single study. Publication bias was evaluated graphically by funnel plot analysis (Figures S1, S2, S3) and then statistically using Begg’s test [15]. An asymmetric funnel plot would suggest the possibility of small studies not being published due to unfavorable results.

Subset analyses were planned for predefined variables, including (i) location of study (Asia versus Europe versus United States), (ii) study period (prior to 1990s versus 1990s versus 2000s), (iii) proportion of Child Pugh C cirrhosis (<10% versus ≥10%), (iv) type of surveillance tests (ultrasound versus ultrasound and AFP), and (v) length of surveillance interval (≥6 months versus >6 months). Study location and study period were evaluated given potential differences in available technology over time. Subset analyses were planned for type of surveillance tests and surveillance interval, as both have been previously demonstrated to affect surveillance efficacy [16]. Finally, we included
population characteristics, such as Child Pugh class, given that liver function is a known determinant of treatment eligibility and survival [5]. All data analysis was conducted using Stata 11.

**Results**

**Literature Search**

The computer-assisted search yielded 5,999 potentially relevant titles published between January 1, 1989 and January 1, 2014. After initial review, 246 titles were potentially appropriate, and these abstracts were reviewed. Eighty-four publications underwent full-text review, and 45 were excluded. The remaining 39 met all inclusion criteria (Figure 1). Searches of annual meeting abstracts yielded seven relevant abstracts with sufficient data for inclusion. Finally, recursive literature searches identified one additional article that met inclusion criteria, producing a total of 47 studies for inclusion.

On the basis of evaluation of funnel plots (Figures S1, S2, S3), we could not exclude the possibility of publication bias. Most small studies produced larger positive effects than studies with large sample sizes, particularly for receipt of curative therapy and overall survival. There was a paucity of small “negative” studies, i.e., those failing to show a significant association between HCC surveillance and early detection, curative treatment, or overall survival. However, the association between HCC surveillance and each outcome remained statistically significant when only including large studies (i.e., those with at least 100 patients with HCC) (Table 4).

**Study Characteristics**

Characteristics of included studies are described in Table 1. We identified 47 studies, with a total of 15,158 patients, assessing the impact of HCC surveillance on at least one outcome of interest [17–63]. Of these patients, 6,284 (41.4%) HCC were detected by surveillance and 8,874 (58.6%) presented symptomatically or were
| Author      | Year | Study Location | Design of Data Collection | Surveillance Method | Number of Patients with HCC | Proportion with Child C Cirrhosis | Definition of Early Stage HCC | Proportion of Patients with Early HCC | Proportion of Patients with Curative Treatment | Factors Adjusted for in Survival Analysis | Overall Survival |
|------------|------|----------------|---------------------------|---------------------|-----------------------------|----------------------------------|-------------------------------|------------------------------------|--------------------------------------------|------------------------------------------|-----------------|
| Sinigal    | 2013 | United States  | Prospective               | HCV-assOCIated HCC  | US and AFP every 6 mo       | 83 (72 S, 11 NS)                | 0%                            | Milan criteria                    | 72% Surv                    | 73% Non surv                           | NR             |
| Wong       | 2013 | Australia      | Retrospective             | HCC                 | US and AFP every 6–12 mo    | 215 (70 S, 145 NS)              | 9.2%                          | NR                                 | NR                          | 68% Surv                    | 30% Non surv                           | Median 30-mo surv |
| Ayala      | 2012 | Lebanon        | Retrospective             | HCC                 | Imaging within 15 mo       | 112 (54 S, 58 NS)               | NR                           | BCLC Stage A                      | 54% Surv                    | 46% Non surv                           | None           |
| Bouali     | 2012 | Tunisia        | Retrospective             | HCC                 | US every 4–12 mo           | 105 (25 S, 80 NS)               | NR                           | Unifocal tumor <3 cm             | 46% Surv                    | 21% Non surv                           | None           |
| Miguel     | 2012 | Spain          | Prospective               | HCC                 | US and AFP every 6 mo       | 110 (56 S, 54 NS)               | 3.6%                          | BCLC Stage A                      | 71% Surv                    | 48% Non surv                           | Median 32-mo surv |
| Sarkar     | 2012 | United States  | Retrospective             | HBV-associated HCC  | US or AFP within year      | 51 (14 S, 37 NS)                | NR                           | Milan criteria                    | 79% Surv                    | 19% Non surv                           | Median 21-mo surv |
| El-Serag   | 2011 | United States  | Retrospective             | HCV-associated HCC  | US or AFP within 6 mo and 7–24 mo | 912 (580 S, 332 NS)              | NR                           | NR                                 | NR                          | NR                                      | 67% 3-year surv |
| Kallwitz   | 2011 | United States  | Retrospective             | HCC                 | Not defined                 | 167 (97 S, 70 NS)               | NR                           | Milan criteria                    | 81% Surv                    | 35% Non surv                           | Age Race Year of diagnosis |
| Reau       | 2011 | United States  | Retrospective             | HCC                 | Not defined                 | 110 (65 S, 45 NS)               | NR                           | Milan criteria                    | 94% Surv                    | 36% Non surv                           | Mortality HR 0.52 |
| Smirniotopoulos | 2011 | United States  | Retrospective             | HCC                 | Imaging within year        | 89 (42 S, 47 NS)                | NR                           | TNM Stage I–II                    | 98% Surv                    | 60% Non surv                           | 95% CI 0.29–0.95 |
| Stroffolini | 2011 | Italy          | Prospective               | HCC                 | US and AFP                 | 411 (257 S, 154 NS)             | 8.6%                          | Milan criteria                    | OR 3.1 (95% CI 1.9–5.2) | NR                                      | None           |
| Yang       | 2011 | United States  | Retrospective             | HCC                 | Imaging within year        | 442 (136 S, 307 NS)             | 10.6%                         | Milan criteria                    | 58% Surv                    | 20% Non surv                           | 65% 3-year surv |

**Table 1. Characteristics of included studies.**
| Author         | Year | Study Location | Design of Data Collection | Surveillance Method | Number of Patients with HCC | Proportion with Child C Cirrhosis | Definition of Early Stage HCC | Proportion of Patients with Early HCC | Proportion of Patients with Curative Treatment | Factors Adjusted for in Survival Analysis | Overall Survival |
|----------------|------|----------------|----------------------------|---------------------|-----------------------------|----------------------------------|--------------------------------|-------------------------------------|-----------------------------------------------|---------------------------------------------|------------------|
| Rodriguez      | 2011 | Spain          | Prospective               | HCC                 | 136 (86 S, 50 NS)            | 5.9%                             | BCLC A                         | 73% Surv                            | 32% Non surv                              | N/A                                         | NR               |
| Goh            | 2010 | Singapore      | Prospective               | HCC                 | 1,113 (186 S, 927 NS)        | NR                               | TNM Stage I-II                 | 59% Surv                            | 25% Non surv                              | None                                        | Median 35-mo surv 4-mo non surv |
| Jou            | 2010 | United States  | Retrospective             | HCC                 | 319 (98 S, 221 NS)           | 10.0%                            | BCLC Stage A                   | 53% Surv                            | 46% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Kuo            | 2010 | Taiwan         | Retrospective             | HCC                 | 1,436 (318 S, 1,118 NS)      | 6.2%                             | BCLC Stage A                   | 69% Surv                            | 27% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Noda           | 2010 | Japan          | Retrospective             | HCV-associated HCC  | 240 (124 S, 116 NS)          | NR                               | Milan criteria                 | 48% Surv                            | 44% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Tong           | 2010 | United States  | Retrospective             | HCC                 | 278 (219 S, 59 NS)           | 2.9%                             | Milan criteria                 | 65% Surv                            | 25% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Tong           | 2010 | United States  | Retrospective             | HBV-associated HCC  | 78 (26 S, 52 NS)             | 5.1%                             | Milan criteria                 | 62% Surv                            | 20% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Zapata         | 2010 | Spain          | Retrospective             | HCC                 | 85 (40 S, 45 NS)             | 2.6%                             | Milan criteria                 | 70% Surv                            | 27% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Chan           | 2008 | Hong Kong      | Prospective               | Viral-associated HCC| 1,366 (441 S, 925 NS)        | 8.1%                             | NR                             | 64% Surv                            | 36% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Pascual        | 2008 | Spain          | Prospective               | HCC                 | 290 (117 S, 173 NS)          | 14.5%                            | Unifocal tumor < 5 cm           | 60% Surv                            | 24% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Silveira       | 2008 | United States  | Retrospective             | PBC-associated HCC  | 33 (17 S, 16 NS)             | 47% hepatic decompensation       | Milan criteria                 | 47% Surv                            | 56% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Stravitz       | 2008 | United States  | Retrospective             | HCC                 | 279 (172 S, 107 NS)          | 15%                              | Milan criteria                 | 69% Surv                            | 26% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Wong           | 2008 | Hong Kong      | Retrospective             | Viral-associated HCC| 472 (79 S, 393 NS)           | 4.7%                             | NR                             | 67% Surv                            | 30% Non surv                              | Etiology Liver function AFP Tumor stage Treatment | 59% 3-year surv 29% 3-year non surv |
| Author          | Year | Study Location | Design of Data Collection | Cohort | Surveillance Method | Number of Patients with HCC | Proportion with Child C Cirrhosis | Definition of Early Stage HCC | Proportion of Patients with Early HCC | Proportion of Patients with Curative Treatment | Factors Adjusted for in Survival Analysis | Overall Survival |
|-----------------|------|----------------|---------------------------|--------|--------------------|-----------------------------|----------------------------------|-----------------------------------|-------------------------------------|---------------------------------------------|-------------------------------------------|------------------|
| Caumes          | 2007 | France         | Prospective HCC           | Not defined | Not defined     | 106 (30 S, 76 NS)             | 22.7%                            | Unifocal tumor < 3 cm            | 33% Surv 4% Non surv            | 37% Surv 18% Non surv              | N/A                                | NR               |
| Cho             | 2007 | Korea          | Retrospective HCC         | Not defined | Not defined     | 71 (16 S, 55 NS)             | 0%                               | BCLC Stage A                   | 65% Surv 2% Non surv                | NR                               | Age Gender Cirrhosis Viral hepatitis Liver function Tumor stage | Median 60-mo surv 16-mo non surv |
| Davila          | 2007 | United States  | Retrospective HCC         | Imaging or AFP within 3 years | 157 (44 S, 113 NS) | 36.3%                        | Unifocal tumor                  | 50% Surv 38% Non surv             | NR                                | None                              | 30% 3-year surv 21% 3-year non surv    |
| Gellert         | 2007 | Australia      | Retrospective HCC         | US or AFP | 149 (27 S, 122 NS) | 14.1%                        | Milan criteria                  | 44% Surv 20% Non surv             | 19% Surv 10% Non surv              | Liver function Tumor size Treatment  | Median 13-mo surv 4-mo non surv    |
| Leykum          | 2007 | United States  | Retrospective HCC         | HCV-associated HCC | Imaging or AFP within year | 72 (16 S, 56 NS) | NR                              | Milan criteria                  | 100% Surv 21% Non surv             | NR                                | Tertiary care Subspecialty care Psychosis Tumor stage Treatment | 30% 3-year surv 15% 3-year non surv |
| Ando            | 2006 | Japan          | Retrospective HCC         | Imaging and AFP | 574 (392 S, 182 NS) | NR                            | Milan criteria                  | 73% Surv 26% Non surv             | 57% Surv 26% Non surv             | None                              | 62% 3-year surv 38% 3-year non surv    |
| Cheung          | 2006 | Hong Kong      | Retrospective HCC         | US and AFP | 223 (97 S, 126 NS) | 23.3%                        | TNM Stage I-II                  | 47% Surv 21% Non surv             | NR                                | Hepatitis B Smoking Alcohol Liver function Alkaline phosphatase Tumor stage Treatment | Median 21-mo surv 4-mo non surv |
| Tanaka          | 2006 | Japan          | Retrospective HCC         | HCV-related HCC | US and AFP every 6 mo | 384 (182 S, 202 NS) | 2.6%                            | Milan criteria                  | 86% Surv 50% Non surv             | 76% Surv 46% Non surv              | Liver function AFP Tumor stage Lead time | 67% 3-year surv 51% 3-year non surv |
| Toyoda          | 2006 | Japan          | Retrospective HCC         | Imaging or AFP | 1,641 (1,050 S, 591 NS) | 15.1%                        | TNM Stage I-II                  | 58% Surv 20% Non surv             | 44% Surv 14% Non surv             | Age Gender Liver function Tumor stage Treatment | 51% 3-year surv 27% 3-year non surv |
| Taura           | 2005 | Japan          | Retrospective HCC         | US and AFP every 3–12 mo | 271 (178 S, 93 NS) | 5.9%                         | NR                              | NR                                | 51% Surv 20% Non surv             | Liver function | 67% 3-year surv 53% 3-year non surv    |
| Author            | Year | Study Location | Design of Data Collection | Number of Patients with HCC | Proportion with Child C Cirrhosis | Definition of Early Stage HCC | Number of Patients with Early HCC | Proportion of Patients with Curative Treatment | Factors Adjusted for in Survival Analysis | Overall Survival |
|-------------------|------|----------------|---------------------------|-----------------------------|----------------------------------|-------------------------------|-------------------------------------|-------------------------------------------|-------------------------------------------|------------------|
| Van Vlierberghe   | 2005 | Belgium        | Prospective HCC           | 131 (47 S, 84 NS)           | NR                               | Milan criteria                | 60% Surv                            | 31% Non surv                             | None                                      | 58% 1-year surv |
| Yu                | 2004 | Taiwan         | Retrospective HCC          | 680 (164 S, 516 NS)         | NR                               | NR                            | 51% Surv                            | 29% Non surv                             | Age, Cirrhosis, Viral hepatitis, Liver function, AFP, Lead time | 49% 3-year surv |
| Trevisani         | 2002 | Italy          | Retrospective HCC          | 821 (370 S, 451 NS)         | 8.9%                             | Milan criteria                | 65% Surv                            | 31% Non surv                             | Gender, Hepatitis B, Liver function, AFP, Tumor stage, Treatment, Lead time | 48% 3-year surv |
| Bolondi           | 2001 | Italy          | Retrospective HCC          | 165 (61 S, 104 NS)          | 12.1%                            | NR                            | NR                                  | 48% 32% Non surv                         | Liver function                                         | 45% 3-year surv |
| Giannini          | 2000 | Italy          | Retrospective HCV-related HCC | 61 (34 S, 27 NS)     | NR                               | NR                            | NR                                  | 68% 41% Non surv                         | None                                      | Median 23-mo surv |
| Wong              | 2000 | United States  | Retrospective HCC          | 91 (16 S, 75 NS)            | NR                               | TNM Stage I-II                | 62% Surv                            | 45% Non surv                             | None                                      | 65% 3-year surv |
| Durand            | 1995 | France         | Retrospective HCC          | 61 (7 S, 54 NS)             | NR                               | Unifocal tumor < 3 cm          | 14% Surv                            | 17% Non surv                             | None                                      | 30% 1-year surv |
| Garcia Gullon     | 1995 | Spain          | Retrospective HCC          | 99 (34 S, 65 NS)            | 27.3%                            | Unifocal tumor < 3 cm          | 59% Surv                            | 11% Non surv                             | N/A                                      | NR              |
| Onodera           | 1994 | Japan          | Retrospective HCC          | 116 (19 S, 97 NS)           | NR                               | LCSGJ Stage I-II              | 79% Surv                            | 31% Non surv                             | None                                      | 57% 3-year surv |
| Unoura            | 1993 | Japan          | Retrospective HCC          | 112 (44 S, 68 NS)           | NR                               | NR                            | NR                                  | NR                                        | None                                      | Median 32-mo surv |
| Martinez Cerezo   | 1993 | Spain          | Retrospective HCC          | 135 (43 S, 92 NS)           | NR                               | Unifocal tumor < 5 cm          | 47% Surv                            | 15% Non surv                             | N/A                                      | NR              |
| Tanaka            | 1990 | Japan          | Retrospective HCC          | 105 (22 S, 83 NS)           | 0%                               | Unifocal tumor < 4 cm          | 68% Surv                            | 23% Non surv                             | N/A                                      | NR              |

HR, hazard ratio; LCSGJ, Liver Cancer Study Group of Japan; N/A, not applicable; NR, not reported; NS, non surveillance group; S, surveillance group; US, ultrasound. 

doi:10.1371/journal.pmed.1001624.t001
found incidentally outside of a surveillance protocol. HCC was detected by surveillance in 51% (1,614 of 3,162) of patients among studies in the United States, 45% (1,182 of 2,611) of patients among studies in Europe, 37% (3,312 of 8,804) of patients among studies in Asia, and 30% (176 of 581) of patients among other studies. Most studies (n = 39) were retrospective in nature, although nine had collected data about HCC outcomes prospectively. Fifteen studies were conducted in the United States, 15 in Asia, 13 throughout Europe, and four studies were conducted in other countries. Of the 39 studies that specified surveillance tests used, only ten included ultrasound alone and most used a combination of ultrasound and/or AFP.

Twenty-nine studies reported details regarding the proportion of patients with HCC and underlying cirrhosis. Overall, 90.9% (6,732 of 7,411) of patients had underlying cirrhosis, although rates ranged from 32.4% to 100% between studies. Twenty-seven studies reported information regarding liver function among included patients. The majority (55.5%) of patients (6,018 of 10,853) had Child Pugh A cirrhosis, with higher rates among those who received HCC surveillance (61.3% versus 51.4%, p < 0.001) (2,607 of 4,255 for surveillance versus 3,213 of 6,247 for non-surveillance). Similarly, patients who received HCC surveillance had lower rates of Child Pugh class C cirrhosis (8.5% versus 11.7%, p < 0.001) (310 of 3,647 for surveillance versus 592 of 5,062 for non-surveillance).

Quality Assessment

The quality assessment for included studies is described in Table 2. Out of a maximum 9-point score, 27 studies had quality scores of 5 or 6, 12 studies had a score of 7, and eight had quality scores of 8 or 9. Most studies had appropriate cohort selection, including representativeness of the surveillance cohort and selection of the non-surveillance cohort. All studies ascertained surveillance exposure and HCC outcomes through medical records. However, only six of the 36 studies assessing the impact of surveillance on survival controlled for both lead-time bias and Child Pugh liver function. An additional 13 studies controlled for liver function alone but 17 studies did not control for either factor. Furthermore, 20 studies did not have sufficient follow-up length to assess survival and 27 studies failed to adequately account for patients lost to follow-up.

Association between HCC Surveillance and Detection of Tumors at an Early Stage

Thirty-eight studies, with a total of 10,904 patients, included data on tumor stage stratified by receipt of HCC surveillance [17,18,20,21,23–26,28,29,31–50,52–55,61,63]. Twenty-four studies defined early stage using BCLC or Milan criteria [17,18,24,29,32–35,37,38,41,44,45,47,52,53,61,63], while six studies used other staging systems (e.g., tumor node metastases [TNM]) [23,31,39,46,54,59], and eight used operational definitions (e.g., unifocal lesion less than 3 cm) [20,21,25,26,28,36,40,50] (Table 1). The 24 studies using BCLC or Milan criteria included a total of 6,573 patients, of whom 2,815 (44.1%) were diagnosed by surveillance.

When including all 38 studies, patients who underwent surveillance were significantly more likely to be found at an early stage (OR 2.11, 95% CI 1.88–2.33); however, there was significant heterogeneity (I² = 73%, p < 0.001) (Table 1). When only including studies using BCLC or Milan criteria, there was little change in effect size (OR 2.08, 95% CI 1.80–2.37) or heterogeneity (I² = 77%, p < 0.001). On subset analysis of the six studies using BCLC to define early stage, the pooled odds ratio was also stable at 1.96 (95% CI 1.41–2.73) [18,24,32,34,37,42]. One notable outlier was a study by Cho and colleagues, which had a relative risk of 37.81 (95% CI 5.27–271.13) [24]. Only data on patients younger than 30 years old were reported for this study, so we excluded it from further analyses. Heterogeneity (I² = 78%, p < 0.001) could not be improved with removal of additional studies, and meta-influence analysis did not suggest undue influence of any single study. Among the 23 remaining studies, HCC surveillance was significantly associated with early stage tumor detection (OR 2.08, 95% CI 1.80–2.37) (Figure 2). The pooled rate of early stage HCC among patients undergoing surveillance was 70.9% (95% CI 69.3%–72.6%) (2,047 of 2,885 patients), compared to only 29.9% (95% CI 28.4–31.4%) (1,034 of 3,463 patients) among those who presented symptomatically and/or diagnosed incidentally.

We performed pre-planned subset analyses according to study design, location of study, study period, and type of surveillance tests used (Table 4). Rates of early tumor detection were consistent across study location (OR 2.22 [95% CI 1.75–2.81]) among studies conducted in Asia [17,34,38,49] versus 2.00 [95% CI 1.70–2.35] among studies in Europe [37,42,55,57,63] versus 2.31 [95% CI 1.79–2.99] among studies in the United States [32,33,35,41,43,44,45,47,52,53,61,63], study period (OR 2.22 [95% CI 1.77–2.79] among studies assessing surveillance in the 1990s [17,29,49,53,55] versus 2.18 [95% CI 1.86–2.56] among studies assessing surveillance after 2000 [18,32–35,37,38,41–43,45,47,52,57,61,63]), and type of surveillance tests (OR 2.04 [95% CI 1.55–2.68] with ultrasound alone [18,32,38,47,61] versus 2.16 [95% CI 1.80–2.60] with ultrasound and/or AFP [17,29,34,35,37,42–45,49,52,53,55,63]). There was no significant difference in the association between HCC surveillance and early stage tumor detection by study design (p = 0.10), with patients detected by surveillance being more likely to be found at an early stage in both subgroups. The pooled odds ratio was 2.30 (95% CI 1.98–2.67) among retrospective studies [17,18,29,32–35,37,38,41–43,45,47,52,57,61,63], compared to 1.70 (95% CI 1.29–2.26) among studies using surveillance after 2000 [18,32–35,37,38,41–43,45,47,52,57,61,63], and type of surveillance tests (OR 2.04 [95% CI 1.55–2.68] with ultrasound alone [18,32,38,47,61] versus 2.16 [95% CI 1.80–2.60] with ultrasound and/or AFP [17,29,34,35,37,42–45,49,52,53,55,63]).

Association between HCC Surveillance and Receipt of Curative Treatment

Thirty-four studies, with a total of 12,187 patients, assessed the association of HCC surveillance with receipt of curative therapy [17,19,20–22,26,28–38,40,43,44,46,47,49,50,51,53–55,58–60]. Of the included patients, 4,655 (38.2%) were detected by surveillance and 7,532 (61.8%) presented symptomatically or were diagnosed incidentally. Patients diagnosed by surveillance were significantly more likely to undergo curative therapy, with a pooled odds ratio of 2.24 (95% CI 1.99–2.52) (Figure 3; Table 1). We found heterogeneity among studies (I² = 75.3%, p < 0.001). Meta-influence analysis did not suggest undue influence of any single study. Although four studies [33,35,46,60] appeared to be outliers, we did not find clinical heterogeneity justifying their exclusion. The association between HCC surveillance and receipt of curative therapy did not substantially change if these four studies had been excluded (OR 2.11, 95% CI 1.89–2.37). The pooled rate of curative treatment receipt among patients undergoing surveillance was 51.6% (95% CI 50.2–53.0%) (2,402 of 4,655), compared to only 23.7% (95% CI 22.8%–24.7%) (1,790 of 7,532) among those who presented symptomatically or were diagnosed incidentally.

Among the 16 cohort studies that reported both early detection (using Milan or BCLC criteria) and curative treatment rates [17,29,32–35,37,38,43,44,47,49,52,53,61,63], we found a
Table 2. Quality assessment of studies.

| Author     | Year   | Surveillance Cohort Representative | Non-surveillance Cohort Selection | Ascertainment Of Exposure | Outcome Not Initially Present | Control for Potential Confounders* | Assessment of Outcome | Follow-up Period | Follow-up of Cohort |
|------------|--------|-----------------------------------|-----------------------------------|---------------------------|-------------------------------|------------------------------------|----------------------|------------------|----------------------|
| Singal     | 2013 [45] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 1                | 1                    |
| Wong       | 2013 [60] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 0                | 1                    |
| Ayala      | 2012 [18] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 0                | 1                    |
| Bouali     | 2012 [20] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 1                | 1                    |
| Miguel     | 2012 [37] | 1                                 | 0                                 | 1                         | 1                             | 1                                  | 1                    | 1                | 1                    |
| Sarkar     | 2012 [43] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 1                | 1                    |
| El-Serag   | 2011 [27] | 1                                 | 1                                 | 1                         | 1                             | 2                                  | 1                    | 1                | 1                    |
| Kallwitz   | 2011 [33] | 1                                 | 1                                 | 1                         | 1                             | 0                                  | 1                    | 1                | 1                    |
| Reau       | 2011 [41] | 1                                 | 1                                 | 1                         | 1                             | 0                                  | 1                    | 1                | 1                    |
| Smirniotopoulos | 2011 [46] | 1                                 | 1                                 | 1                         | 1                             | 0                                  | 1                    | 1                | 1                    |
| Stroffolini | 2011 [48] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 1                | 1                    |
| Yang       | 2011 [50] | 1                                 | 1                                 | 1                         | 1                             | 0                                  | 1                    | 1                | 1                    |
| Rodriguez  | 2011 [42] | 1                                 | 1                                 | 1                         | 1                             | 0                                  | 1                    | 1                | 1                    |
| Goh        | 2010 [31] | 1                                 | 1                                 | 1                         | 1                             | 0                                  | 1                    | 0                | 1                    |
| Jou        | 2010 [32] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 0                | 1                    |
| Kuo        | 2010 [34] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 1                | 1                    |
| Noda       | 2010 [38] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 0                | 1                    |
| Tong       | 2010 [52] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 0                | 1                    |
| Tong       | 2010 [53] | 1                                 | 1                                 | 1                         | 1                             | 2                                  | 1                    | 0                | 1                    |
| Zapata     | 2010 [63] | 1                                 | 1                                 | 1                         | 1                             | 1                                  | 1                    | 0                | 1                    |
| Author            | Year        | Surveillance Cohort Representative | Non-surveillance Cohort Selection | Ascertainment Of Exposure | Outcome Not Initially Present | Control for Potential Confounders⁶ | Assessment of Outcome | Follow-up Period | Follow-up of Cohort |
|-------------------|-------------|-----------------------------------|-----------------------------------|---------------------------|------------------------------|-----------------------------------|----------------------|----------------|-------------------|
| Chan              | 2008 [22]   | 1                                 | 1                                 | 1                         | 0                            | 1                                 | 1                    | 1              | 0                 |
| Pascual           | 2008 [40]   | 1                                 | 1                                 | 1                         | 1                            | 0                                 | 0                    | 1              | 0                 |
| Silveira          | 2008 [44]   | 1                                 | 1                                 | 1                         | 1                            | 0                                 | 0                    | 1              | 0                 |
| Stravitz          | 2008 [47]   | 1                                 | 1                                 | 1                         | 0                            | 1                                 | 0                    | 1              | 0                 |
| Wong              | 2008 [58]   | 1                                 | 1                                 | 1                         | 2                            | 1                                 | 1                    | 0              | 0                 |
| Caumes            | 2007 [21]   | 1                                 | 1                                 | 1                         | 0                            | 1                                 | 1                    | 1              | 0                 |
| Cho               | 2007 [24]   | 0                                 | 1                                 | 1                         | 1                            | 1                                 | 1                    | 1              | 0                 |
| Davila            | 2007 [25]   | 1                                 | 1                                 | 1                         | 1                            | 0                                 | 1                    | 1              | 0                 |
| Gellert           | 2007 [29]   | 1                                 | 1                                 | 1                         | 1                            | 1                                 | 1                    | 1              | 1                 |
| Leykum            | 2007 [35]   | 1                                 | 1                                 | 1                         | 0                            | 1                                 | 0                    | 0              | 0                 |
| Ando              | 2006 [17]   | 1                                 | 1                                 | 1                         | 0                            | 1                                 | 1                    | 0              | 0                 |
| Cheung            | 2006 [23]   | 1                                 | 1                                 | 1                         | 1                            | 1                                 | 1                    | 1              | 0                 |
| Tanaka            | 2006 [49]   | 1                                 | 1                                 | 1                         | 1                            | 1                                 | 0                    | 0              | 0                 |
| Toyoda            | 2006 [54]   | 1                                 | 1                                 | 1                         | 1                            | 1                                 | 1                    | 1              | 0                 |
| Taura             | 2005 [51]   | 1                                 | 1                                 | 1                         | 1                            | 1                                 | 1                    | 1              | 0                 |
| Van Vlierberghe   | 2005 [57]   | 1                                 | 1                                 | 1                         | 0                            | 1                                 | 1                    | 0              | 0                 |
| Yu                | 2004 [62]   | 1                                 | 1                                 | 1                         | 1                            | 2                                 | 1                    | 1              | 1                 |
| Trevisani         | 2002 [55]   | 1                                 | 1                                 | 1                         | 1                            | 2                                 | 1                    | 1              | 1                 |
| Bolondi           | 2001 [19]   | 1                                 | 1                                 | 1                         | 1                            | 1                                 | 1                    | 0              | 0                 |
| Giannini          | 2000 [30]   | 1                                 | 1                                 | 1                         | 1                            | 0                                 | 1                    | 0              | 0                 |
moderately strong positive correlation between early detection rates and curative treatment rates between studies (Pearson’s correlation \( r = 0.54 \)) (Figure S4). This finding suggests the association between surveillance and receipt of curative treatment is mediated by improved early tumor detection rates.

We performed pre-planned subset analyses, according to study design, location of study, study period, and type of surveillance tests used (Table 4). Rates of curative therapy receipt were consistent across study design (OR 2.18 [95% CI 1.94–2.45] among retrospective studies [17,19,20,26,28–30,32–36,38,43,44,46,47,49,50,51,53–55,58–63] versus 2.37 [95% CI 1.51–3.72] among prospective studies [21,22,31,37,40]), study period (OR 2.12 [95% CI 1.25–3.61] among studies assessing surveillance prior to 1990 [26,44,50,54] versus 2.23 [95% CI 1.87–2.67] among studies assessing surveillance in the 1990s [17,19,20,22,28–31,36,40,49,51,53,55,59,60,62] versus 2.13 [95% CI 1.85–2.44] among studies assessing surveillance after 2000 [21,32,34,35,37,38,43,46,47,58,61,63]), and type of surveillance tests (OR 2.23 [95% CI 1.83–2.71] with ultrasound alone [20,28,32,38,46,47,61,62] versus 2.19 [95% CI 1.89–2.53] with ultrasound and/or AFP [17,19,22,26,29–31,34–37,40,43,44,49,50,51,53–55,58–60,63]). Finally, there was no significant difference in the strength of association between HCC surveillance and curative therapy receipt by study location \( (p = 0.20) \); patients detected by surveillance were significantly more likely to receive curative therapy in both subgroups. The pooled odds of curative therapy were 1.87 (95% CI 1.51–2.31) for studies conducted in Europe [19,21,26,28,30,36,37,40,55,63], 2.19 (95% CI 1.84–2.61) for studies conducted in Asia [17,22,31,34,38,49,50,51,54,58,62], and 2.52 (95% CI 1.99–3.20) for studies conducted in the United States [32,33,35,43,44,46,47,53,59,61].

### Association between HCC Surveillance and Overall Survival

Thirty-six studies, with a total of 13,361 patients (40.9% \( [n = 5,466] \) detected via surveillance), included data on survival stratified by receipt of HCC surveillance [17–20,22–27,29–31,33–35,37–40,43,44,47,49,51–62]. There was substantial variability in reporting of survival data, with several studies reporting 1-year and/or 3-year survival rates, some reporting median survival without confidence intervals, and others showing a Kaplan Meier curve (Table 1). The most commonly reported survival outcome was 3-year survival, so this was used for further analysis. Three-year survival rates were estimated from Kaplan Meier curves if data were not otherwise presented. Among these 23 studies, HCC surveillance was significantly associated with improved survival, with a pooled odds ratio of 1.90 (95% CI 1.67–2.13) for 3-year survival (Figure 4) [17,19,22,25,27,29,35,38–40,43,44,47,49,51–55,58,59,61,62]. The pooled 3-year survival rate was 50.8% among the 4,735 patients who underwent HCC surveillance, compared to only 27.9% among the 6,115 patients without prior surveillance \( (p < 0.001) \).

We performed pre-planned subset analyses, according to location of study, study period, proportion of Child Pugh C cirrhosis, and study quality (Table 4). The pooled 3-year survival rates for patients with and without surveillance were the highest among studies conducted in Asia [17,22,25,27,35,38,49,51,54,58,62] (57.4% and 31.7%, respectively) \((1,693 of 2,947 for surveillance versus 1,340 of 4,237 for non-surveillance, intermediate among studies from Europe [19,40,55] (47.3% and 21.8%, respectively) \((259 of 548 for surveillance versus 159 of 728 for non-surveillance), and the lowest among studies conducted in the United States [25,27,35,43,44,47,52,53,59,61] (36.5% and 18.2%, respectively) \((453 of 1,240 for surveillance versus 210 of 1,154 for non-surveillance).
Pooled 3-year survival rates were 51.1% (555/1086) and 25.4% (179/704) for surveillance and non-surveillance groups among studies assessing surveillance prior to 1990 [39,44,54], 57.6% (1,122/1,947) and 32.2% (893/2,773), respectively, among studies assessing surveillance during the 1990s [17,19,22,40,49,51,53,55,59], and 42.8% (728/1,702) and 24.1% (637/2,638) among those assessing surveillance after 2000 [25,27,34,35,38,43,47,52,58,61]. There were 15 studies reporting the proportion of Child C patients and data regarding 3-year survival rates [19,22,25,34,40,44,47,49,51–55,58,61]. As anticipated, 3-year survival rates were inversely related to the proportion of patients with Child C cirrhosis. The pooled 3-year survival rates were 57.0% (1,033 of 1,813 patients) and 29.2% (960 of 3,293 patients) in patients with and without surveillance, respectively, among the eight studies with less than 10% Child Pugh C patients [22,34,49,51–53,55,58]. In the seven studies with more than 10% Child Pugh C patients, the 3-year survival rates were only 49.8% (795 of 1,597 patients) and 22.0% (311 of 1,411 patients), respectively [19,25,40,44,47,54,61]. Finally, we evaluated survival according to study quality, with high-quality studies defined as those with a score of 7–9 [27,34,40,44,47,51,53,55,58,62] and >low-quality studies defined as those with scores less than 7 [17,19,22,25,35,38,39,43,47,52,54,59,61].

**Table 1.** Pooled Odds for Early Detection

| Study                  | Odds Ratio (95% CI) |
|------------------------|---------------------|
| Trevisani 2002 [55]    | 2.10 (1.80 - 2.46)  |
| Van Vlierberghe 2005 [57] | 1.92 (1.29 - 2.86)  |
| Ando 2006 [17]         | 2.84 (2.20 - 3.65)  |
| Tanaka 2006 [49]       | 1.71 (1.48 - 1.99)  |
| Leykum 2007 [35]       | 4.43 (2.69 - 7.27)  |
| Gellert 2007 [29]      | 2.17 (1.25 - 3.75)  |
| Stravitz 2008 [47]     | 2.62 (1.88 - 3.66)  |
| Silveira 2008 [44]     | 0.84 (0.43 - 1.63)  |
| Kuo 2010 [34]          | 2.56 (2.27 - 2.90)  |
| Tong 2010 [52]         | 2.57 (1.64 - 4.02)  |
| Noda 2010 [38]         | 2.00 (1.61 - 2.48)  |
| Jou 2010 [32]          | 1.86 (1.47 - 2.36)  |
| Zapata 2010 [63]       | 2.62 (1.55 - 4.44)  |
| Tong 2010 [53]         | 3.20 (1.70 - 6.04)  |
| Stroffolini 2011 [48]  | 3.10 (1.90 - 5.20)  |
| Yang 2011 [61]         | 2.97 (2.27 - 3.89)  |
| Kallwitz 2011 [33]     | 2.28 (1.64 - 3.17)  |
| Reau 2011 [41]         | 2.64 (1.77 - 3.93)  |
| Rodriguez 2011 [42]    | 2.29 (1.50 - 3.50)  |
| Miguel 2012 [37]       | 1.48 (1.07 - 2.05)  |
| Ayala 2012 [18]        | 1.15 (0.80 - 1.67)  |
| Sarkar 2012 [43]       | 4.15 (2.02 - 8.54)  |
| Singal 2013 [45]       | 0.99 (0.67 - 1.47)  |

**Figure 2.** Association between HCC surveillance and early tumor detection rates.

doi:10.1371/journal.pmed.1001624.g002

Pooled 3-year survival rates were 51.1% (555/1086) and 25.4% (179/704) for surveillance and non-surveillance groups among studies assessing surveillance prior to 1990 [39,44,54], 57.6% (1,122/1,947) and 32.2% (893/2,773), respectively, among studies assessing surveillance during the 1990s [17,19,22,40,49,51,53,55,59], and 42.8% (728/1,702) and 24.1% (637/2,638) among those assessing surveillance after 2000 [25,27,34,35,38,43,47,52,58,61]. There were 15 studies reporting the proportion of Child C patients and data regarding 3-year survival rates [19,22,25,34,40,44,47,49,51–55,58,61]. As anticipated, 3-year survival rates were inversely related to the proportion of patients with Child C cirrhosis. The pooled 3-year survival rates were 57.0% (1,033 of 1,813 patients) and 29.2% (960 of 3,293 patients) in patients with and without surveillance, respectively, among the eight studies with less than 10% Child Pugh C patients [22,34,49,51–53,55,58]. In the seven studies with more than 10% Child Pugh C patients, the 3-year survival rates were only 49.8% (795 of 1,597 patients) and 22.0% (311 of 1,411 patients), respectively [19,25,40,44,47,54,61]. Finally, we evaluated survival according to study quality, with high-quality studies defined as those with a score of 7–9 [27,34,40,44,47,51,53,55,58,62] and >low-quality studies defined as those with scores less than 7 [17,19,22,25,35,38,39,43,47,52,54,59,61].
High-quality and low-quality studies had similar 3-year survival rates in the non-surveillance groups (28.8% versus 26.9%, respectively, $p = 0.09$) (965 of 3,346 patients for high-quality studies and 744 of 2,769 patients for low-quality studies). However, 3-year survival rates were significantly lower in the surveillance groups in high quality studies than low-quality studies (45.6% versus 54.7%, respectively, $p < 0.001$) (927 of 2,031 patients for high-quality studies versus 1,478 of 2,704 patients for low-quality studies).

Six studies evaluated any potential benefit of surveillance on survival, after adjusting for lead-time bias (Table 3) [27,49,53,58,62]. Among these studies, HCC surveillance was still associated with a significant improvement in survival (3-year survival).
rates 39.7% versus 29.1%, \( p < 0.001 \) (556 of 1,401 patients for surveillance versus 567 of 1,946 for non-surveillance) \( p < 0.001 \). El-Serag and colleagues reported improved survival when assuming a tumor doubling time of 70 days \( \text{OR} 0.81, 95\% \text{ CI} 0.70–0.94 \) [27]. Assuming a tumor doubling time of 90 days, surveillance was associated with improved survival in studies by Wong \( p = 0.04 \) [58] and Tanaka \( p = 0.02 \) [49]. Tong and colleagues found significantly improved 3-year survival \( 62.5\% \) versus \( 36.6\%, \ p = 0.007 \) after adjusting for a lead-time of 3.9 months, which was based on tumor doubling time among their patients [53]. Yu and colleagues also found significantly reduced mortality at 3 years among those with surveillance \( \text{OR} 0.35, 95\% \text{ CI} 0.24–0.49 \) [62]. Adjusting for lead-time bias (239 days for 6-month surveillance and 98 days for annual surveillance), Trevisani and colleagues found patients undergoing surveillance had a median survival of 30 months, which was significantly better than the 20-month median survival among patients

### Figure 4. Association between HCC surveillance and survival.

doi:10.1371/journal.pmed.1001624.g004

| Study                  | Odds Ratio (95% CI)       |
|------------------------|---------------------------|
| Onodera 1994 [39]      | 3.51 (1.95 - 6.33)        |
| Wong 2000 [59]         | 3.35 (1.83 - 6.14)        |
| Bolondi 2001 [19]      | 1.39 (0.94 - 2.08)        |
| Trevisani 2002 [55]    | 2.09 (1.71 - 2.55)        |
| Yu 2004 [62]           | 1.19 (0.98 - 1.43)        |
| Taura 2005 [51]        | 1.27 (1.02 - 1.58)        |
| Ando 2006 [17]         | 1.64 (1.34 - 2.00)        |
| Tanaka 2006 [49]       | 1.31 (1.11 - 1.56)        |
| Toyoda 2006 [54]       | 1.88 (1.62 - 2.17)        |
| Davila 2007 [25]       | 1.39 (0.78 - 2.48)        |
| Leykum 2007 [35]       | 2.19 (0.83 - 5.77)        |
| Chan 2008 [22]         | 2.14 (1.89 - 2.42)        |
| Pascual 2008 [40]      | 3.63 (2.35 - 5.62)        |
| Silveira 2008 [44]     | 3.14 (1.05 - 9.38)        |
| Stravitz 2008 [47]     | 2.15 (1.39 - 3.32)        |
| Wong 2008 [58]         | 2.02 (1.45 - 2.81)        |
| Kuo 2010 [34]          | 2.04 (1.79 - 2.32)        |
| Noda 2010 [38]         | 1.42 (1.16 - 1.74)        |
| Tong 2010 [52]         | 2.02 (1.25 - 3.26)        |
| Tong 2010 [53]         | 1.68 (1.05 - 2.69)        |
| El-Serag 2011 [27]     | 1.47 (1.09 - 1.97)        |
| Yang 2011 [61]         | 4.05 (3.05 - 5.39)        |
| Sarkar 2012 [43]       | 2.64 (1.33 - 5.27)        |

**Pooled Odds of 3-year Survival**

I-squared = 81.6% (95% CI 73.3–87.3%)

\( 1.90 \) (1.67 - 2.17)
with incidentally discovered tumors \((p<0.001)\) or the 9-month median survival among patients who presented symptomatically \((p<0.001)\) [55].

**Discussion**

To the best of our knowledge, our meta-analysis is the first to critically examine available literature and characterize the potential impact of HCC surveillance on outcomes in patients with cirrhosis. We demonstrated HCC surveillance was associated with significant improvement in early tumor detection and receipt of curative therapies. Most importantly, HCC surveillance was associated with a significant improvement in overall survival. However, there are limitations in current literature, including many studies having insufficient duration of follow-up to adequately assess survival and the majority not adjusting for liver function or lead-time bias. Overall, in the absence of randomized data of surveillance efficacy, our meta-analysis provides sufficient evidence to support guidelines that recommend HCC surveillance in patients with cirrhosis.

The lack of randomized data supporting HCC surveillance in cirrhotic patients has caused some providers to question its benefit, which may contribute to low utilization rates. Prior studies have reported HCC surveillance rates below 20% in the United States, with lower rates among primary care physicians than gastroenterologists/hepatologists [64–68]. However, a lack of randomized data does not necessarily equate to a lack of efficacy. For example, colonoscopy is widely embraced for colorectal cancer screening, without randomized data, based on cohort and case-control studies as well as extrapolation of fecal occult blood test data [69–71]. HCC surveillance fulfills all criteria established by the World Health Organization for a surveillance program [72]: the disease burden of HCC is an important health problem, there is an identifiable target population, surveillance is accepted by patients and providers, surveillance achieves an acceptable level of accuracy, there are standardized recall procedures, surveillance is affordable, there is an advantage of treating occult HCC, and surveillance reduces mortality. Our meta-analysis highlights consistent improvements in early tumor detection, receipt of curative therapy, and overall survival with HCC surveillance among patients with cirrhosis. In light of these data, a randomized controlled trial of HCC surveillance could be deemed unethical. In fact, prior attempts at a randomized trial were unsuccessful, as patients refused participation and desired surveillance after the benefits and harms were discussed [73].

We found substantial statistical heterogeneity between studies, suggesting benefits of surveillance may not be uniform among all patients. Several studies included patients with Child C cirrhosis, which may explain some heterogeneity in regard to treatment eligibility and survival. Trevisani and colleagues demonstrated the survival benefit of HCC surveillance was most marked in patients with Child A cirrhosis [55]. Those with Child C cirrhosis failed to achieve a significant benefit, given lower treatment eligibility rates and higher competing risk of liver-related mortality. Surveillance is not recommended in patients with Child C cirrhosis unless they are transplant candidates [5], so their inclusion in several studies may have mitigated reported benefits of surveillance on treatment eligibility and overall survival.

Furthermore, the risk of HCC may not be uniform across patients and etiologies of liver disease [74]. For example, patients with HCV cirrhosis have a higher risk of HCC than those with alcohol-induced cirrhosis or NASH [75,76]. Predictive models have been created using several risk factors but are limited by moderate accuracy to date [77,78]. Similarly, surveillance is performed with ultrasound and AFP in all patients despite variations in accuracy among patients. Ultrasound is less sensitive in obese patients and those with advanced fibrosis, whereas AFP may be less accurate among HCV positive patients [8,79]. Accurate assessment of HCC risk and surveillance performance characteristics may allow personalized surveillance programs, which could optimize benefits and cost-effectiveness of HCC surveillance. Surveillance may be avoided in low-risk patients, whereas high-risk patients could benefit from a more intensive surveillance regimen.

On subgroup analysis for the association between HCC surveillance and overall survival, we found substantial differences according to study location. We did not find any significant variation in study quality \((p=0.37)\) or size \((p=0.07)\) by study location that might help explain the differences. Further studies are needed to explore this heterogeneity, as there are several potential explanations. There are differences in patient populations, such as higher rates of obesity and NASH-related cirrhosis in the United States than Europe and Asia [80], which may affect treatment response and recurrence rates. There are also differential rates and choice of curative treatment among patients found at an early stage, which can influence response rates, recurrence rates, and overall survival [81].

**Table 3.** Studies assessing survival benefit of surveillance after adjusting for lead time bias.

| Author          | Tumor Doubling Time | Estimated Lead Time | Survival Rates | Statistical Significance |
|-----------------|---------------------|---------------------|----------------|-------------------------|
| El-Serag 2011   | 70 days             | 70 days             | Median survival 298 vs. 130 days | OR 0.81 (95% CI 0.70–0.94) |
| Tong 2010       | 216 days            | 118 days            | 3-year survival 62.5% vs. 36.6% | \(p=0.007\) |
| Wong 2008       | 90 days             | 236 days            | 2-year survival 49.4% vs. 28.6% | \(p=0.035\) |
| Tanaka 2006     | 90 days             | 238 days            | Median survival 6.3 vs. 5.3 years \(^a\) | \(p=0.016\) |
| Yu 2004         | Not reported        | Not reported        | 3-year survival 49.0% vs. 41.2% \(^a\) | OR 0.33 (95% CI 0.24–0.49) |
| Trevisani 2002  | Not reported        | 98–239 days         | Median survival 30 vs. 20 mo. | \(p<0.001\) |

\(^a\)Estimated from Kaplan Meier curve.
doi:10.1371/journal.pmed.1001624.t003
Table 4. Subgroup analyses for association between HCC surveillance and early detection, curative treatment rates, and survival.

| Variable                      | Subgroup                        | Odds Ratio |
|-------------------------------|---------------------------------|------------|
| **Early detection**           |                                 |            |
| Study design                  | Prospective [37,42,45,55,57]     | OR 1.70 (95% CI 1.29–2.26) |
|                               | Retrospective [17,18,29,32–35,38,41,43,44,47,49,52,53,61,63] | OR 2.30 (95% CI 1.98–2.67) |
| Location of study             | Asia [17,34,38,49]               | OR 2.22 (95% CI 1.75–2.81) |
|                               | Europe [37,42,55,57,63]          | OR 2.00 (95% CI 1.70–2.35) |
|                               | United States [32,33,35,41,43–45,47,52,53,61] | OR 2.31 (95% CI 1.79–2.99) |
| Study period                  | During 1990s [17,29,49,53,55]    | OR 2.22 (95% CI 1.77–2.79) |
|                               | After 2000 [18,32–35,37,38,41–43,45,47,52,57,61,63] | OR 2.18 (95% CI 1.86–2.56) |
| Type of surveillance test     | Ultrasound alone [18,32,38,47,61] | OR 2.04 (95% CI 1.55–2.68) |
| Study size                    | More than 100 patients [17,18,29,32–34,37,38,41,42,47,48,50,52,55,57,61] | OR 2.13 (95% CI 1.88–2.39) |
| **Receipt of curative treatment** |                                 |            |
| Study design                  | Prospective [21,22,31,37,40]     | OR 2.37 (95% CI 1.51–3.72) |
|                               | Retrospective [17,19,20,26,28–30,32–36,38,43,44,46,47,49–51,53–55,58–63] | OR 2.18 (95% CI 1.94–2.45) |
| Location of study             | Asia [17,22,31,34,38,49–51,54,58,62] | OR 2.19 (95% CI 1.84–2.61) |
|                               | Europe [19,21,26,28,30,36,37,40,55,63] | OR 1.87 (95% CI 1.51–2.31) |
|                               | United States [32,33,35,43,44,46,47,53,59,61] | OR 2.52 (95% CI 1.99–3.20) |
| Study period                  | Prior to 1990 [26,44,50,54]      | OR 2.12 (95% CI 1.25–3.61) |
|                               | During 1990s [17,19,20,22,28–31,36,40,49,51,53,55,59,60,62] | OR 2.23 (95% CI 1.87–2.67) |
|                               | After 2000 [21,32,34,35,37,38,43–47,58,61,63] | OR 2.13 (95% CI 1.85–2.44) |
| Type of surveillance test     | Ultrasound alone [20,28,32,38,46,47,61,62] | OR 2.23 (95% CI 1.83–2.71) |
| Study size                    | More than 100 patients [17,19–22,29,31–34,36–38,40,47,49–51,54,55,58,61,62] | OR 2.18 (95% CI 1.91–2.48) |
| **3-year survival**           |                                 |            |
| Location of study             | Asia [17,22,34,38,39,49,51,54,58,62] | 57.4% for surveillance vs. 31.7% for non-surveillance |
|                               | Europe [19,40,55]                | 47.3% for surveillance vs. 21.8% for non-surveillance |
|                               | United States [25,27,35,43,44,47,52,53,59,61] | 36.5% for surveillance vs. 18.2% for non-surveillance |
| Study period                  | Prior to 1990 [39,44,54]         | 51.1% for surveillance vs. 25.4% for non-surveillance |
|                               | During 1990s [17,19,20,22,28–31,34–37,40,43,44,49–51,53–55,58–60,63] | 57.6% for surveillance vs. 32.2% for non-surveillance |
|                               | After 2000 [25,27,34,35,38,43,47,52,58,61] | 42.8% for surveillance vs. 24.1% for non-surveillance |
| Liver function                | Child C cirrhosis ≦10% cohort [19,25,40,44,47,54,61] | 57.0% for surveillance vs. 29.2% for non-surveillance |
|                               | Child C cirrhosis <10% cohort [22,34,49,51,52,53,55,58] | 49.8% for surveillance vs. 22.0% for non-surveillance |
| Overall study quality         | Low quality [17,19,22,25,35,38,39,43,47,52,54,59,61] | 54.7% for surveillance vs. 26.9% for non-surveillance |
|                               | High quality [27,34,40,44,49,51,53,55,58,62] | 45.6% for surveillance vs. 28.8% for non-surveillance |
| Lead time bias assessment     | Did not adjust for lead time bias [17,19,22,25,34,35,38–40,43,44,47,51,52,54,59,61] | 55.5% for surveillance vs. 27.4% for non-surveillance |
|                               | Adjusted for lead time bias [27,49,53,55,58,62] | 39.7% for surveillance vs. 29.1% for non-surveillance |
| Study size                    | More than 100 patients [17,19,22,25,27,34,38–40,47,49,51,52,54,55,58,61,62] | 50.7% for surveillance vs. 39.0% for non-surveillance |

doi:10.1371/journal.pmed.1001624.t004
Results from our study must be interpreted within the limitations of included studies. Many studies failed to adequately account for patients lost to follow-up and did not have sufficient follow-up to adequately assess survival. Furthermore, several studies used operational definitions of surveillance, such as ultrasound or AFP in a two-year period, which were not consistent with guideline recommendations. Guidelines recommend ultrasound every 6 months to optimize sensitivity, and AFP should not be used alone without imaging [5]. Clear definitions and measures should be used in future studies to better interpret and quantify any benefits of HCC surveillance.

All studies in this meta-analysis were non-randomized cohort studies, with potential for lead-time and length-time biases. However, several studies demonstrated a significant improvement in survival after statistically adjusting for lead-time bias [82]. Furthermore, lead-time bias may be less problematic for patients diagnosed at an early stage by surveillance, given the selective availability of curative options at that stage. Liver transplantation, surgical resection, and RFA have been associated with 5-year survival rates approaching 70% but are only available for patients with early stage tumors [5]. The survival benefit of HCC surveillance is contingent on subsequent receipt of curative therapy [83]. This relationship is further highlighted by the strong positive correlation between early tumor detection and curative treatment rates among studies in our meta-analysis.

Study results were also potentially limited by selection bias, with a differential distribution of liver function and/or performance status among surveillance and non-surveillance groups. Surveillance group patients were less likely to have Child Pugh C liver disease, although liver function was not reported in all studies. Other studies have suggested that patients with hepatic decompensation are more likely to have recognized cirrhosis and therefore receive surveillance [68]. We did not find information regarding functional status in any of the included studies. Detailed reporting of performance status and liver function is important given both are key factors in determining treatment eligibility. Patients with poor functional status or Child C cirrhosis, if not transplant candidates, should be excluded given HCC surveillance is not recommended in these subgroups. Finally, a comprehensive assessment of surveillance should weigh benefits and harms; however, no study in our meta-analysis assessed downstream harms. Although ultrasound and AFP have minimal direct harms, there are potential downstream harms from recall policies (e.g., complications of liver biopsy or cross-sectional imaging) that should be considered in future studies.

In summary, current data suggest that HCC surveillance is associated with significant improvement in early tumor detection. By facilitating receipt of curative therapy in a higher proportion of patients, HCC surveillance is associated with a significant improvement in overall survival. There are notable limitations in current literature, including many studies failing to adequately adjust for lead-time bias. However, the preponderance of data that consistently demonstrate benefits should provide sufficient rationale to recommend HCC surveillance, even in the absence of a randomized controlled trial among patients with cirrhosis.

Supporting Information

Figure S1 Funnel plot for HCC surveillance and early detection.

Figure S2 Funnel plot for HCC surveillance and receipt of curative treatment.

Figure S3 Funnel plot for HCC surveillance and survival.

Figure S4 Association between early detection by HCC surveillance and receipt of curative treatment.

Table S1 MOOSE checklist.

Author Contributions

Conceived and designed the experiments: AS. Performed the experiments: AS AP JT. Analyzed the data: AS JT. Contributed to the writing of the manuscript: AS AP JT. Wrote the first draft of the manuscript: AS. Contributed to the writing of the manuscript: AS AP JT. Agree with manuscript results and conclusions: AS AP JT.
48. Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, et al. (2008) Surveillance for hepatocellular carcinoma in patients with cirrhosis: is early detection by screening effective? Am J Gastroenterol 103: 2258–2266.

47. Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, et al. (2008) Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther 29: 573–585.

46. Chung TK, Lai CL, Wong BC, Fung J, Yuen MF (2006) Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in French patients. Dig Dis Sci 51: 706–707.

45. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, et al. (2011) Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 59: 962–969.

44. Garcia Guillon C, Rendon Unceta F, Martin Herrera I, Soría de la Cruz M, Macias M, et al. (1995) Utilidad de la ecografía en el diagnóstico precoz del hepatocarcinoma en pacientes con cirrosis hepática. Revista española de enfermedades digestivas 87: 798–801.

43. Gellert L, Jalaludin B, Levy M (2007) Hepatocellular carcinoma in Sydney South West: late presentation and poor outcome for most. Intern Med J 37: 516–522.

42. Giannini E, Arzani L, Borro P, Botta F, Fasoli A, et al. (2000) Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? Hepatogastroenterology 47: 1395–1396.

41. Goh B, Chang J, Ong W (2010) Surveillance for hepatocellular carcinoma in chronic liver disease is associated with increased diagnosis of early HCC and a trend of improvement in survival: a study of 113 cases. Hepatol Med 5: 113S–118S.

40. Jou JH, Chen PH, Jazwinski A, Bouneva I, Smith AD, et al. (2010) Rates of hepatocellular carcinoma surveillance outcomes. Hepatology 54: 1410A.

39. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma surveillance and treatment: improving survival for patients with cirrhosis. Eur J Cancer 46: 744–751.

38. Leykam LK, El-Serag HB, Cornell J, Papadopoulou KP (2007) Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 5: S58–S62.

37. Martinez Cerezo F, Puig M, Martinez Nogueras A, Tomas A, Pamplona J, et al. (1993) Valor de la ecografía en el diagnóstico precoz del carcinoma hepatocelular. Revista española de enfermedades digestivas 83: 311–314.

36. Korsak C, Gaba M, Huang Y (2011) Surveillance for hepatocellular carcinoma is associated with surveillance, lesion size, amination and transpland in an area with limited organ availability. Hepatology 54: 1381A.

35. Kuo LY, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma surveillance and treatment: improving survival for patients with cirrhosis. Eur J Cancer 46: 744–751.

34. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma surveillance and treatment: improving survival for patients with cirrhosis. Eur J Cancer 46: 744–751.

33. Kucik J, Galan J, Fan L, Younossi Z, Lee WM, et al. (2011) Are hepatocellular carcinoma surveillance programs effective at detecting early hepatocellular carcinoma: a study from a community-based clinic. Dig Dis Sci 56: 826–835.

32. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

31. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

30. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

29. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

28. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

27. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

26. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

25. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

24. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

23. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

22. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

21. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

20. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

19. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

18. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

17. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

16. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

15. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

14. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

13. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

12. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

11. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

10. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

9. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

8. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

7. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

6. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

5. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

4. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

3. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

2. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.

1. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, et al. (2010) Hepatocellular carcinoma screening outcomes. Hepatology 54: 1998–2004.
76. White DL, Kanwal F, El-Serag HB (2012) Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10: 1342–1359 e1342.
77. Lee E, Edward N, Singal AG, Laviere MS, Volk M (2013) Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin Gastroenterol Hepatol 11: 437–440.
78. Singal AG, Mukherjee A, Joseph Elmunzer B, Higgins PD, Lek AS, et al. (2013) Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 108: 1723–1730.
79. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, et al. (2013) Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. In press.
80. Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10: 686–690.
81. Tan D, Yopp A, Beg MS, Gopal P, Singal AG (2013) Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 38: 705–712.
82. Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Housami N, et al. (2008) Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 168: 98–104.
83. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, et al. (2003) Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 10: 204–209.
Editors’ Summary

Background. Hepatocellular cancer (HCC) is the commonest form of primary liver cancer—a type of cancer that starts when a cell in the liver acquires genetic changes that allow it to grow uncontrollably. Primary liver cancer is the third leading cause of cancer-related death worldwide, killing more than 600,000 people every year. The symptoms of HCC are vague and rarely appear until the cancer has spread throughout the liver. They include unexplained weight loss, feeling sick, tiredness, and jaundice (yellowing of the skin and eyes). If liver cancer is diagnosed in its early stages, it can be treated by surgically removing part of the liver, by liver transplantation, or by a procedure called radiofrequency ablation in which an electric current is used to destroy the cancer cells. However, most people are diagnosed with HCC when the cancer is advanced and cannot be treated. These individuals are given palliative treatment to relieve pain and discomfort. Although most patients who are diagnosed with HCC at an early stage survive more than 5 years, patients with more advanced HCC have an average survival less than one year. The exact cause of HCC is unknown, but it is thought to be related to cirrhosis (scarring) of the liver. This condition is the end result of long-term (chronic) liver damage caused by, for example, alcohol abuse or infection with hepatitis B virus (HBV).

Why Was This Study Done? Because HCC tends to be untreatable when it is diagnosed at a late stage, if the tumor can be found early by regularly measuring blood levels of alpha fetoprotein (a liver cancer biomarker) and using ultrasound, outcomes for patients at high risk of developing HCC might be improved. Indeed, American and European guidelines recommend HCC surveillance with ultrasound every 6 months in patients with HBV infection and/or cirrhosis. However, although randomized controlled trial results support HCC surveillance among patients infected with HBV, no randomized trials have investigated its use among patients with cirrhosis. Here, the researchers use predefined criteria to identify all the published cohort and case-control studies (two types of non-randomized studies) that have examined the impact of HCC surveillance on outcomes in patients with cirrhosis. They then pool the data from these studies using a statistical approach called meta-analysis to estimate whether HCC surveillance is associated with improvements in early tumor detection, curative treatment receipt, and survival rates among patients with cirrhosis.

What Did the Researchers Do and Find? The researchers identified 47 studies that examined the association of HCC surveillance with outcomes in 15,158 patients with cirrhosis who developed HCC. In 41.4% of these patients, HCC was detected by surveillance. Among patients who had undergone HCC surveillance, the pooled rate of early detection was 70.9%, whereas among patients who had not undergone surveillance but who were diagnosed incidentally or who presented with symptoms, the pooled rate of early detection was 29.9%. The researchers calculated that the pooled odds (chances) of early detection among patients undergoing surveillance compared to early detection among patients not undergoing surveillance was 2.08 (an odds ratio [OR] of 2.08). The pooled rate of curative treatment receipt among patients undergoing surveillance was 51.3% compared to only 23.8% among patients not undergoing surveillance (OR 2.24). Finally, among those patients for whom the relevant data were available, 50.8% of patients who had undergone HCC surveillance but only 28.2% of those who had not undergone surveillance survived for at least 3 years after diagnosis (OR 1.90).

What Do These Findings Mean? These findings show that HCC surveillance is associated with significant improvements (improvements that are unlikely to have happened by chance) in early tumor detection, receipt of curative treatment, and overall survival among patients with cirrhosis. Importantly, the association with improved overall survival remained significant after adjusting for the possibility that patients who underwent surveillance died at the same time as they would have done without surveillance but appeared to survive longer because they were diagnosed earlier (this is called adjustment for lead-time bias). These results must be interpreted cautiously, however, because many of the studies included in the meta-analysis had insufficient follow-up to assess survival adequately, not all the studies adjusted for lead-time bias, and none of the studies assessed potential downstream harms of HCC surveillance such as complications of liver biopsies. Nevertheless, overall, these findings provide sufficient evidence to support guidelines that recommend regular HCC surveillance for patients with cirrhosis.

Additional Information. Please access these websites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1001624.

- The US National Cancer Institute provides information about all aspects of cancer, including detailed information for patients and professionals about primary liver cancer and about screening for primary liver cancer (in English and Spanish)
- The American Cancer Society also provides information about liver cancer (available in several languages)
- The UK National Health Service Choices website provides information about primary liver cancer and about cirrhosis (including patient stories)
- Cancer Research UK (a not-for-profit organization) also provides detailed information about primary liver cancer
- MedlinePlus provides links to further resources about liver cancer and cirrhosis (in English and Spanish)
- Information is available at the American Liver Foundation
- American Association for the Study of Liver Diseases provides practice guidelines